Non-Small Cell Lung Cancer New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations Ulas D. Bayraktar, MD 2025-03-31
Non-Small Cell Lung Cancer New Drug: Ivonescimab for PD-L1 Positive NSCLC Ulas D. Bayraktar, MD 2025-03-14
Non-Small Cell Lung Cancer New Protocol: Osimertinib with Ramucirumab for EGFR-Mutated NSCLC Ulas D. Bayraktar, MD 2025-03-02
Non-Small Cell Lung Cancer New Reference: Zenocutuzumab for NRG1 Fusion-Positive Cancer Ulas D. Bayraktar, MD 2025-02-07
Non-Small Cell Lung Cancer Pancreatic Cancer New Drug: Zenocutuzumab for advanced NRG1 fusion positive NSCLC and Pancreatic Cancer Ulas D. Bayraktar, MD 2024-12-06
Non-Small Cell Lung Cancer New Indication: Osimertinib after Chemoradiotherapy in NSCLC Ulas D. Bayraktar, MD 2024-09-30
Non-Small Cell Lung Cancer New Drug: Lazertinib for EGFR mutated NSCLC Ulas D. Bayraktar, MD 2024-08-27
Non-Small Cell Lung Cancer New Drug: Repotrectinib for ROS1-fusion positive NSCLC Ulas D. Bayraktar, MD 2024-06-21
Non-Small Cell Lung Cancer New Indication: Perioperative Durvalumab for NSCLC Ulas D. Bayraktar, MD 2023-11-20
